Efgartigimod Alfa

26 trials 10 recruiting LOncology Orphan designation

Filter these 26 trials by condition, phase, country and more.

Open in Search →

26 Registered trials

10 Recruiting

13 Completed trials

6 Sponsors

26 Countries

Phase III

Phase II/III

Phase II

Phase III: 12 Phase II/III: 7 Phase II: 6 Phase IV: 1

Indications tested

Myasthenia gravis 7 Endocrine ophthalmopathy 2 Ocular myasthenia 1 Idiopathic inflammatory myopathy 1

Sponsors using this IMP

Argenx 22 Bellvitge University Hospital 1 Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V. 1 Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL 1 Janssen - Cilag International 1 Medizinische Hochschule Hannover 1

All trials — page 2

26 total

An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasth… Ended

2024-510932-36-00 Phase III 7 countries Argenx
A long-term study to assess the safety and efficacy of efgartigimod in adult patients with primary immune thrombocytopenia (an autoimmune di… Ended

2024-511504-17-00 Phase III 4 countries Argenx

Showing 25–26 of 26 trials

← All drugs A–Z